PL378290A1 - Ciekłe preparaty białek wiążących czynnik martwicy nowotworu - Google Patents

Ciekłe preparaty białek wiążących czynnik martwicy nowotworu

Info

Publication number
PL378290A1
PL378290A1 PL378290A PL37829004A PL378290A1 PL 378290 A1 PL378290 A1 PL 378290A1 PL 378290 A PL378290 A PL 378290A PL 37829004 A PL37829004 A PL 37829004A PL 378290 A1 PL378290 A1 PL 378290A1
Authority
PL
Poland
Prior art keywords
binding proteins
necrosis factor
tumor necrosis
liquid formulations
formulations
Prior art date
Application number
PL378290A
Other languages
English (en)
Other versions
PL213501B1 (pl
Inventor
Fabrizio Samaritani
Rio Alessandra Del
Rita Agostinetto
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Publication of PL378290A1 publication Critical patent/PL378290A1/pl
Publication of PL213501B1 publication Critical patent/PL213501B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL378290A 2003-02-28 2004-02-11 Wodny preparat bialka wiazacego czynnik martwicy nowotworu i sposób jego wytwarzania PL213501B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03100505 2003-02-28

Publications (2)

Publication Number Publication Date
PL378290A1 true PL378290A1 (pl) 2006-03-20
PL213501B1 PL213501B1 (pl) 2013-03-29

Family

ID=32921619

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378290A PL213501B1 (pl) 2003-02-28 2004-02-11 Wodny preparat bialka wiazacego czynnik martwicy nowotworu i sposób jego wytwarzania

Country Status (22)

Country Link
US (3) US8937045B2 (pl)
EP (1) EP1603596B1 (pl)
JP (1) JP4980048B2 (pl)
KR (1) KR20050105486A (pl)
CN (1) CN100563712C (pl)
AR (1) AR043418A1 (pl)
AT (1) ATE394123T1 (pl)
BR (1) BRPI0407649A (pl)
CA (1) CA2515539A1 (pl)
DE (1) DE602004013557D1 (pl)
EA (1) EA009079B1 (pl)
ES (1) ES2304602T3 (pl)
HK (1) HK1085677A1 (pl)
HR (1) HRP20050706A2 (pl)
IL (1) IL170414A (pl)
MX (1) MXPA05009135A (pl)
NO (1) NO20054440L (pl)
PL (1) PL213501B1 (pl)
RS (1) RS51041B (pl)
UA (1) UA82503C2 (pl)
WO (1) WO2004075918A1 (pl)
ZA (1) ZA200506504B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
SG175188A1 (en) * 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
ME02506B (me) 2010-11-11 2017-02-20 Abbvie Biotechnology Ltd VISOKA KONCETRACIJA TEČNIH FORMULACIJA ANTI TNF alfa ANTITIJELA
DK2726090T3 (da) * 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
JP6220789B2 (ja) 2011-10-18 2017-10-25 コヒラス・バイオサイエンシズ・インコーポレイテッド 糖およびポリオールの組合せによって安定化されたエタネルセプト製剤
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
EP4218937A3 (en) * 2011-10-31 2023-10-25 F. Hoffmann-La Roche AG Anti-il13 antibody formulations
CA2878508A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
CN104902914B (zh) 2012-09-11 2019-01-01 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
WO2014064637A1 (en) 2012-10-26 2014-05-01 Lupin Limited Stable pharmaceutical composition of tnfr:fc fusion protein
WO2015198456A1 (ja) 2014-06-26 2015-12-30 丸石製薬株式会社 安定性を改善したロクロニウム製剤
RU2724900C1 (ru) * 2019-10-24 2020-06-26 Маруиси Фармасьютикал Ко., Лтд. Препарат рокурония с улучшенной стабильностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
ATE212231T1 (de) * 1995-07-14 2002-02-15 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
JP2000510113A (ja) 1996-05-08 2000-08-08 エフ・ホフマン―ラ ロシュ アーゲー ＴＮＦＲ―Ｉｇによる喘息の治療
CA2273850A1 (en) * 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
ES2618832T3 (es) * 2002-02-27 2017-06-22 Immunex Corporation Composición TNFR-FC estabilizada que comprende arginina

Also Published As

Publication number Publication date
HRP20050706A2 (en) 2005-12-31
EP1603596A1 (en) 2005-12-14
ZA200506504B (en) 2006-12-27
MXPA05009135A (es) 2005-10-20
KR20050105486A (ko) 2005-11-04
EP1603596B1 (en) 2008-05-07
UA82503C2 (uk) 2008-04-25
CN1774266A (zh) 2006-05-17
US9512215B2 (en) 2016-12-06
NO20054440L (no) 2005-09-26
IL170414A (en) 2009-11-18
JP4980048B2 (ja) 2012-07-18
US20170020960A1 (en) 2017-01-26
ATE394123T1 (de) 2008-05-15
CA2515539A1 (en) 2004-09-10
RS51041B (sr) 2010-10-31
CN100563712C (zh) 2009-12-02
DE602004013557D1 (de) 2008-06-19
US8937045B2 (en) 2015-01-20
RS20050662A (en) 2007-11-15
BRPI0407649A (pt) 2006-02-21
AR043418A1 (es) 2005-07-27
US20070053906A1 (en) 2007-03-08
EA009079B1 (ru) 2007-10-26
AU2004216483A1 (en) 2004-09-10
EA200501230A1 (ru) 2006-04-28
PL213501B1 (pl) 2013-03-29
WO2004075918A1 (en) 2004-09-10
HK1085677A1 (en) 2006-09-01
JP2006519210A (ja) 2006-08-24
ES2304602T3 (es) 2008-10-16
US20150098950A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
HK1085677A1 (en) Liquid formulations of tumor necrosis factor-binding proteins
IL181779A (en) A group of protein-based medical molecules
IL159894A0 (en) Therapeutic agents comprising pro-apoptotic proteins
IL227988A0 (en) Use of calcitonin in osteoarthritis
HRP20130512T1 (hr) Stabilne tekuä†e formulacije interferona humanog seruma bez albumina
EP1758617A4 (en) STABLE LIQUID AND LYOPHILIZED PROTEIN FORMULATIONS
EP1598074A4 (en) PROTEIN-STABILIZED DEVICE
GB0202633D0 (en) Stabilization of protein preparations
AU2003289742A1 (en) Stable therapeutic proteins
EP1684790A4 (en) HOMOGENEOUS PREPARATIONS OF CHIMERIC PROTEINS
AU2003252072A8 (en) Modulation of protein kinase c-iota expression
EP1605794A4 (en) ARTIFICIAL, LIQUID NAIL
GB0305267D0 (en) Proteins involved in apoptosis
AU2003215452A1 (en) Surface proteins of leptospira
GB0311108D0 (en) Proteins
GB0305387D0 (en) Protein stability and cancer
EP1631235A4 (en) COMPOSITIONS AND METHOD FOR MODULATING THE EXPRESSION OF B7 PROTEIN
SI2251353T1 (sl) Homogeni preparati il-29
GB0305268D0 (en) Proteins involved in apoptosis
GB0305269D0 (en) Proteins involved in apoptosis
ZA200400228B (en) Therapeutic agents comprising pro-apoptotic proteins
GB0306980D0 (en) Proteins
GB0330036D0 (en) Proteins
GB0318686D0 (en) Proteins
GB0300503D0 (en) Proteins